<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040883</url>
  </required_header>
  <id_info>
    <org_study_id>DSPC-SED20130516</org_study_id>
    <nct_id>NCT02040883</nct_id>
  </id_info>
  <brief_title>Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia</brief_title>
  <acronym>TAAS</acronym>
  <official_title>Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingyun Yin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Psychiatric Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve
      Cognitive function in Schizophrenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With atypical antipsychotics for the control group, evaluate cognitive function in
      schizophrenia patients with antipsychotics combined 5-Hydroxytryptamine 1A (5-HT1A) receptor
      partial agonist tandospirone
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement and treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery(MCCB) total score</measure>
    <time_frame>From baseline to 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MATRICS Consensus Cognitive Battery(MCCB) factor score</measure>
    <time_frame>From baseline to 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale(PANSS) total score</measure>
    <time_frame>From baseline to 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale(PANSS) factor score</measure>
    <time_frame>From baseline to 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal and Social Performance Scale(PSP) total score</measure>
    <time_frame>From baseline to 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression(CGI) factor score</measure>
    <time_frame>From baseline to 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Symptom Scale(TESS) factor score</measure>
    <time_frame>From baseline to 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional magnetic resonance imaging(FMRI)</measure>
    <time_frame>From baseline to 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole</intervention_name>
    <description>Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>AAPD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tandospirone</intervention_name>
    <description>Tandospirone，30mg per day</description>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>Sediel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic and Statistical Manual of Mental Disorders-IV Edition (DSM-IV) diagnostic
             criteria for schizophrenia patients.

          -  18-65 years (including 18 and 65), male or female.

          -  Treated with a stable dose of an AAPD for at least three months.

          -  Informed consent was obtained (if the patient is in the acute phase of schizophrenia,
             does not have the capacity, their guardians need sign informed consent).

          -  PANSS negative score ≤60.

        Exclusion Criteria:

          -  Combined AxisⅠmental illness other than schizophrenia;

          -  Taking a mood stabilizer, antidepressants, anticholinergic or anxiolytic drugs, and
             other drugs improve cognitive function;

          -  Suicidal tendencies;

          -  Have severe or unstable heart, liver, kidney, endocrine, blood and other medical
             disease patients

          -  Clinically significant ECG or laboratory abnormalities were

          -  Glaucoma and epilepsy;

          -  Unsupervised or unable to take prescribed medication;

          -  History of alcohol and drug abuse;

          -  Allergic;

          -  Pregnant or lactating woman;

          -  Patients participate in other clinical trials during a month;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingyun Yin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou Psychiatric Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingyun Yin</last_name>
    <email>qingyun2000@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangzhou Psychiatric Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510170</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>qingyun Yin</last_name>
      <email>qingyun2000@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>January 17, 2014</last_update_submitted>
  <last_update_submitted_qc>January 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Psychiatric Hospital</investigator_affiliation>
    <investigator_full_name>Qingyun Yin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Tandospirone</keyword>
  <keyword>Cognitive Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Tandospirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

